Screening Patients for Bipolar Disorder
A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled studies) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. It should be noted that PRISTIQ is not approved for use in treating bipolar depression.
Patient Exposure
PRISTIQ was evaluated for safety in 8,394 patients diagnosed with major depressive disorder who participated in multiple-dose pre-marketing studies, representing 2,784 patient-years of exposure. Of the total 8,394 patients exposed to at least one dose of PRISTIQ; 2,116 were exposed to PRISTIQ for 6 months, representing 1,658 patient-years of exposure, and 421 were exposed for one year, representing 416 patient-years of exposure.
Adverse Reactions Reported as Reasons for Discontinuation of Treatment
In the pre-marketing pooled 8-week placebo-controlled studies in patients with MDD, 1,834 patients were exposed to PRISTIQ (50 to 400 mg). Of the 1,834 patients, 12% discontinued treatment due to an adverse reaction, compared with 3% of the 1,116 placebo-treated patients. At the recommended dose of 50 mg, the discontinuation rate due to an adverse reaction for PRISTIQ (4.1%) was similar to the rate for placebo (3.8%). For the 100 mg dose of PRISTIQ the discontinuation rate due to an adverse reaction was 8.7%.
The most common adverse reactions leading to discontinuation in at least 2% and at a rate greater than placebo of the PRISTIQ treated patients in the short-term studies, up to 8 weeks, were: nausea (4%); dizziness, headache and vomiting (2% each). In a longer-term study, up to 9 months, the most common was vomiting (2%).
Common Adverse Reactions in Placebo-Controlled MDD Studies
The most commonly observed adverse reactions in PRISTIQ treated MDD patients in pre-marketing pooled 8-week, placebo-controlled, fixed-dose studies (incidence ≥ 5% and at least twice the rate of placebo in the 50 or 100 mg dose groups) were: nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders.
Table 2 shows the incidence of common adverse reactions that occurred in ≥ 2% of PRISTIQ treated MDD patients and twice the rate of placebo at any dose in the pre-marketing pooled 8-week, placebo-controlled, fixed dose clinical studies.
Table 2: Common Adverse Reactions (≥ 2% in any Fixed-Dose Group and Twice the Rate of Placebo) in Pre-marketing Pooled MDD 8-Week Placebo-Controlled Studies | Percentage of Patients Reporting Reaction |
|---|
| | PRISTIQ |
|---|
System Organ Class Preferred Term | Placebo (n=636) | 50 mg (n=317) | 100 mg (n=424) | 200 mg (n=307) | 400 mg (n=317) |
|---|
Cardiac disorders |
Blood pressure increased | 1 | 1 | 1 | 2 | 2 |
Gastrointestinal disorders |
Nausea | 10 | 22 | 26 | 36 | 41 |
Dry mouth | 9 | 11 | 17 | 21 | 25 |
Constipation | 4 | 9 | 9 | 10 | 14 |
Vomiting | 3 | 3 | 4 | 6 | 9 |
General disorders and administration site conditions |
Fatigue | 4 | 7 | 7 | 10 | 11 |
Chills | 1 | 1 | <1 | 3 | 4 |
Feeling jittery | 1 | 1 | 2 | 3 | 3 |
Metabolism and nutrition disorders |
Decreased appetite | 2 | 5 | 8 | 10 | 10 |
Nervous system disorders |
Dizziness | 5 | 13 | 10 | 15 | 16 |
Somnolence | 4 | 4 | 9 | 12 | 12 |
Tremor | 2 | 2 | 3 | 9 | 9 |
Disturbance in attention | <1 | <1 | 1 | 2 | 1 |
Psychiatric disorders |
Insomnia | 6 | 9 | 12 | 14 | 15 |
Anxiety | 2 | 3 | 5 | 4 | 4 |
Nervousness | 1 | <1 | 1 | 2 | 2 |
Abnormal dreams | 1 | 2 | 3 | 2 | 4 |
Renal and urinary disorders |
Urinary hesitation | 0 | <1 | 1 | 2 | 2 |
Respiratory, thoracic and mediastinal disorders |
Yawning | <1 | 1 | 1 | 4 | 3 |
Skin and subcutaneous tissue disorders |
Hyperhidrosis | 4 | 10 | 11 | 18 | 21 |
Special Senses |
Vision blurred | 1 | 3 | 4 | 4 | 4 |
Mydriasis | <1 | 2 | 2 | 6 | 6 |
Vertigo | 1 | 2 | 1 | 5 | 3 |
Tinnitus | 1 | 2 | 1 | 1 | 2 |
Dysgeusia | 1 | 1 | 1 | 1 | 2 |
Vascular disorders |
Hot flush | <1 | 1 | 1 | 2 | 2 |
Sexual Function Adverse Reactions
Table 3 shows the incidence of sexual function adverse reactions that occurred in ≥ 2% of PRISTIQ treated MDD patients in any fixed-dose group (pre-marketing pooled 8-week, placebo-controlled, fixed -dose, clinical studies) [see Warnings and Precautions (5.11)].
Table 3: Sexual Function Adverse Reactions (≥ 2% in Men or Women in any PRISTIQ Group) During the On-Therapy Period | | PRISTIQ |
| Placebo (n=239) | 50 mg (n=108) | 100 mg (n=157) | 200 mg (n=131) | 400 mg (n=154) |
Men only |
Anorgasmia | 0 | 0 | 3 | 5 | 8 |
Libido decreased | 1 | 4 | 5 | 6 | 3 |
Orgasm abnormal | 0 | 0 | 1 | 2 | 3 |
Ejaculation delayed | <1 | 1 | 5 | 7 | 6 |
Erectile dysfunction | 1 | 3 | 6 | 8 | 11 |
Ejaculation disorder | 0 | 0 | 1 | 2 | 5 |
Ejaculation failure | 0 | 1 | 0 | 2 | 2 |
Sexual dysfunction | 0 | 1 | 0 | 0 | 2 |
| | PRISTIQ |
| Placebo (n=397) | 50 mg (n=209) | 100 mg (n=267) | 200 mg (n=176) | 400 mg (n=163) |
Women only |
Anorgasmia | 0 | 1 | 1 | 0 | 3 |
Other Adverse Reactions Observed in Premarketing and Postmarketing Clinical Studies
Other infrequent adverse reactions, not described elsewhere in the label, occurring at an incidence of < 2% in MDD patients treated with PRISTIQ were:
Cardiac disorders – Tachycardia.
General disorders and administration site conditions – Asthenia.
Investigations – Weight increased, liver function test abnormal, blood prolactin increased.
Musculoskeletal and connective tissue disorders – Musculoskeletal stiffness.
Nervous system disorders –Syncope, convulsion, dystonia.
Psychiatric disorders – Depersonalization, bruxism.
Renal and urinary disorders – Urinary retention.
Skin and subcutaneous tissue disorders – Rash, alopecia, photosensitivity reaction, angioedema.
In clinical studies, there were uncommon reports of ischemic cardiac adverse reactions, including myocardial ischemia, myocardial infarction, and coronary occlusion requiring revascularization; these patients had multiple underlying cardiac risk factors. More patients experienced these events during PRISTIQ treatment as compared to placebo.
Laboratory, ECG and Vital Sign Changes Observed in MDD Clinical Studies
The following changes were observed in pre-marketing placebo-controlled, short-term MDD studies with PRISTIQ.
Lipids
Elevations in fasting serum total cholesterol, LDL (low density lipoproteins) cholesterol, and triglycerides occurred in the controlled studies. Some of these abnormalities were considered potentially clinically significant.
The percentage of patients who exceeded a predetermined threshold value is shown in Table 4.
Table 4: Incidence (%) of Patients With Lipid Abnormalities of Potential Clinical Significance* | | PRISTIQ |
|---|
| Placebo | 50 mg | 100 mg | 200 mg | 400 mg |
|---|
Total Cholesterol *(Increase of ≥ 50 mg/dl and an absolute value of ≥ 261 mg/dl) | 2 | 3 | 4 | 4 | 10 |
LDL Cholesterol *(Increase ≥ 50 mg/dl and an absolute value of ≥ 190 mg/dl) | 0 | 1 | 0 | 1 | 2 |
Triglycerides, fasting *(Fasting: ≥ 327 mg/dl) | 3 | 2 | 1 | 4 | 6 |
Proteinuria
Proteinuria, greater than or equal to trace, was observed in the pre-marketing fixed-dose controlled studies (see Table 5). This proteinuria was not associated with increases in BUN or creatinine and was generally transient.
Table 5: Incidence (%) of Patients with Proteinuria in the Fixed-dose Clinical Studies | | PRISTIQ |
|---|
| Placebo | 50 mg | 100 mg | 200 mg | 400 mg |
|---|
Proteinuria | 4 | 6 | 8 | 5 | 7 |
Vital Sign Changes
Table 6 summarizes the changes that were observed in placebo-controlled, short-term, pre-marketing studies with PRISTIQ in patients with MDD (doses 50 to 400 mg).
Table 6: Mean Changes in Vital Signs at Final on Therapy for All Short-term, Fixed-dose Controlled Studies | | PRISTIQ |
|---|
| Placebo | 50 mg | 100 mg | 200 mg | 400 mg |
|---|
Blood pressure | | | | | |
Supine systolic bp (mm Hg) | -1.4 | 1.2 | 2.0 | 2.5 | 2.1 |
Supine diastolic bp (mm Hg) | -0.6 | 0.7 | 0.8 | 1.8 | 2.3 |
Pulse rate | | | | | |
Supine pulse (bpm) | -0.3 | 1.3 | 1.3 | 0.9 | 4.1 |
Weight (kg) | 0.0 | -0.4 | -0.6 | -0.9 | -1.1 |
Treatment with PRISTIQ at all doses from 50 mg per day to 400 mg per day in controlled studies was associated with sustained hypertension, defined as treatment-emergent supine diastolic blood pressure (SDBP) ≥90 mm Hg and ≥10 mm Hg above baseline for 3 consecutive on-therapy visits (see Table 7). Analyses of patients in PRISTIQ pre-marketing short-term controlled studies who met criteria for sustained hypertension revealed a consistent increase in the proportion of patients who developed sustained hypertension. This was seen at all doses with a suggestion of a higher rate at 400 mg per day.
Table 7: Proportion of Patients with Sustained Elevation of Supine Diastolic Blood Pressure| Treatment Group | Proportion of Patients with Sustained Hypertension |
|---|
Placebo | 0.5% |
PRISTIQ 50 mg per day | 1.3% |
PRISTIQ 100 mg per day | 0.7% |
PRISTIQ 200 mg per day | 1.1% |
PRISTIQ 400 mg per day | 2.3% |
Orthostatic Hypotension
In the pre-marketing short-term, placebo-controlled clinical studies with doses of 50 to 400 mg, systolic orthostatic hypotension (decrease ≥30 mm Hg from supine to standing position) occurred more frequently in patients ≥65 years of age receiving PRISTIQ (8%, 7/87) versus placebo (2.5%, 1/40), compared to patients <65 years of age receiving PRISTIQ (0.9%, 18/1,937) versus placebo (0.7%, 8/1,218).
Major Depressive Disorder
The efficacy of PRISTIQ as a treatment for depression was established in four 8-week, randomized, double-blind, placebo-controlled, fixed-dose studies (at doses of 50 mg per day to 400 mg per day) in adult outpatients who met the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for major depressive disorder. In the first study, patients received 100 mg (n = 114), 200 mg (n = 116), or 400 mg (n = 113) of PRISTIQ once daily, or placebo (n = 118). In a second study, patients received either 200 mg (n = 121) or 400 mg (n = 124) of PRISTIQ once daily, or placebo (n = 124). In two additional studies, patients received 50 mg (n = 150 and n = 164) or 100 mg (n = 147 and n = 158) of PRISTIQ once daily, or placebo (n = 150 and n = 161).
PRISTIQ showed superiority over placebo as measured by improvement in the 17-item Hamilton Rating Scale for Depression (HAM-D17) total score in four studies and overall improvement, as measured by the Clinical Global Impressions Scale - Improvement (CGI-I), in three of the four studies. In studies directly comparing 50 mg per day and 100 mg per day there was no suggestion of a greater effect with the higher dose and adverse reactions and discontinuations were more frequent at higher doses [see Dosage and Administration (2.1)].
Table 9: Primary Efficacy (HAM-D17) Results for Short-term Studies | | | PRISTIQ |
|---|
| Study No. | Primary Endpoint: HAM-D17 | Placebo | 50 mg/day | 100 mg/day | 200 mg/day | 400 mg/day |
|---|
1 | Baseline Score (SD Standard deviation. ) | 23.1 (2.5) | | 23.2 (2.5) | 22.9 (2.4) | 23.0 (2.2) |
| Difference from Placebo (95% CI Difference between least squares means at final evaluation, calculated as drug response minus placebo response; unadjusted 95% confidence intervals. ) | | | -2.9 Adjusted p-value < 0.05. (-5.1, -0.8) | -2.0 | -3.1 (-5.2, -0.9) |
2 | Baseline Score (SD) | 25.3 (3.3) | | | 24.8 (2.9) | 25.2 (3.2) |
| Difference from Placebo (95% CI) | | | | -3.3 (-5.3, -1.2) | -2.8 (-4.8, -0.7) |
3 | Baseline Score (SD) | 23.0 (2.6) | 23.4 (2.6) | 23.4 (2.6) | | |
| Difference from Placebo (95% CI) | | -1.9 (-3.5, -0.3) | -1.5 | | |
4 | Baseline Score (SD) | 24.3 (2.6) | 24.3 (2.4) | 24.4 (2.7) | | |
| Difference from Placebo (95% CI) | | -2.5 (-4.1, -0.9) | -3.0 (-4.7, -1.4) | | |
Analyses of the relationships between treatment outcome and age and treatment outcome and gender did not suggest any differential responsiveness on the basis of these patient characteristics. There was insufficient information to determine the effect of race on outcome in these studies.
In a longer-term trial (Study 5), adult outpatients meeting DSM-IV criteria for major depressive disorder, who responded to 8 weeks of open-label acute treatment with 50 mg per day desvenlafaxine and subsequently remained stable for 12 weeks on desvenlafaxine, were assigned randomly in a double-blind manner to remain on active treatment or switch to placebo for up to 26 weeks of observation for relapse. Response during the open-label phase was defined as a HAM-D17 total score of ≤ 11 and CGI-I ≤ 2 at the day 56 evaluation; stability was defined as HAM-D17 total score of ≤ 11 and CGI-I ≤ 2 at week 20 and not having a HAM-D17 total score of ≥ 16 or a CGI-I score ≥ 4 at any office visit. Relapse during the double-blind phase was defined as follows: (1) a HAM-D17 total score of ≥ 16 at any office visit, (2) discontinuation for unsatisfactory efficacy response, (3) hospitalized for depression, (4) suicide attempt, or (5) suicide. Patients receiving continued desvenlafaxine treatment experienced statistically significantly longer time to relapse compared with placebo. At 26 weeks, the Kaplan-Meier estimated proportion of relapse was 14% with desvenlafaxine treatment versus 30% with placebo.
Figure 4. Estimated Proportion of Relapses vs. Number of Days since Randomization (Study 5) |
|
In another longer-term trial (Study 6), adult outpatients meeting DSM-IV criteria for major depressive disorder and who responded to 12 weeks of acute treatment with desvenlafaxine were assigned randomly to the same dose (200 or 400 mg per day) they had received during acute treatment or to placebo for up to 26 weeks of observation for relapse. Response during the open-label phase was defined as a HAM-D17 total score of ≤ 11 at the day 84 evaluation. Relapse during the double-blind phase was defined as follows: (1) a HAM-D17 total score of ≥ 16 at any office visit, (2) a CGI-I score of ≥ 6 (versus day 84) at any office visit, or (3) discontinuation from the trial due to unsatisfactory response. Patients receiving continued desvenlafaxine treatment experienced statistically significantly longer time to relapse over the subsequent 26 weeks compared with those receiving placebo. At 26 weeks, the Kaplan-Meier estimated proportion of relapse was 29% with desvenlafaxine treatment versus 49% with placebo.
Figure 5. Estimated Proportion of Relapses vs. Number of Days since Randomization (Study 6) |
|
In a postmarketing study, the efficacy of PRISTIQ at a dose lower than 50 mg per day was evaluated in an 8-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose study in adult outpatients with Major Depressive Disorder. The treatment arms were 25 mg (n=232), 50 mg (n=236), and placebo (n=231). The 50 mg dose was superior to placebo, as measured by the mean change from baseline on the HAMD-17. The 25 mg dose was not superior to placebo.
Suicidal Thoughts and Behaviors
Advise patients and caregivers to look for the emergence of suicidality, especially early during treatment and when the dose is adjusted up or down, and instruct them to report such symptoms to the healthcare provider [see Boxed Warning and Warnings and Precautions (5.1)].
Concomitant Medication
Advise patients taking PRISTIQ not to use concomitantly other products containing desvenlafaxine or venlafaxine. Healthcare professionals should instruct patients not to take PRISTIQ with an MAOI or within 14 days of stopping an MAOI and to allow 7 days after stopping PRISTIQ before starting an MAOI [see Contraindications (4)].
Serotonin Syndrome
Caution patients about the risk of serotonin syndrome, particularly with the concomitant use of PRISTIQ with other serotonergic agents (including triptans, tricyclic antidepressants, opioids, lithium, amphetamines, tryptophan, buspirone, and St. John's Wort supplements) [see Warnings and Precautions (5.2)].
Elevated Blood Pressure
Advise patients that they should have regular monitoring of blood pressure when taking PRISTIQ [see Warnings and Precautions (5.3)].
Increased Risk of Bleeding
Inform patients about the concomitant use of PRISTIQ with NSAIDs, aspirin, other antiplatelet drugs, warfarin, or other coagulants because the combined use of has been associated with an increased risk of bleeding. Advise patients to inform their healthcare providers if they are taking or planning to take any prescription or over-the-counter medications that increase the risk of bleeding [see Warnings and Precautions (5.4)].
Activation of Mania/Hypomania
Advise patients, their families and caregivers to observe for signs of activation of mania/hypomania [see Warnings and Precautions (5.6)].
Discontinuation Syndrome
Advise patients not to abruptly stop taking PRISTIQ without talking first with their healthcare professional. Patients should be aware that discontinuation effects may occur when stopping PRISTIQ, and a dose of 25 mg per day is available for discontinuing therapy [see Warnings and Precautions (5.7) and Adverse Reactions (6.1)].
Sexual Dysfunction
Advise patients that use of PRISTIQ may cause symptoms of sexual dysfunction in both male and female patients. Inform patients that they should discuss any changes in sexual function and potential management strategies with their healthcare provider [see Warnings and Precautions (5.11)].
Switching Patients from Other Antidepressants to PRISTIQ
Discontinuation symptoms have been reported when switching patients from other antidepressants, including venlafaxine, to PRISTIQ. Tapering of the initial antidepressant may be necessary to minimize discontinuation symptoms.
Interference with Cognitive and Motor Performance
Caution patients about operating hazardous machinery, including automobiles, until they are reasonably certain that PRISTIQ therapy does not adversely affect their ability to engage in such activities.
Alcohol
Advise patients to avoid alcohol while taking PRISTIQ [see Drug Interactions (7.3)].
Allergic Reactions
Advise patients to notify their physician if they develop allergic phenomena such as rash, hives, swelling, or difficulty breathing.
Pregnancy
Advise patients to notify their physician if they become pregnant or intend to become pregnant during therapy. Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to PRISTIQ during pregnancy [see Use in Specific Populations (8.1)].
Residual Inert Matrix Tablet
Patients receiving PRISTIQ may notice an inert matrix tablet passing in the stool or via colostomy. Patients should be informed that the active medication has already been absorbed by the time the patient sees the inert matrix tablet.
This product's label may have been updated. For current full prescribing information, please visit www.pfizer.com.
LAB-0452-25.0